Effects of nk1 receptors on gastric motor functions and satiation in healthy humans: Results from a controlled trial with the nk1 antagonist aprepitant

Deepti Jacob, Irene Busciglio, Duane Burton, Houssam Halawi, Ibironke Oduyebo, Deborah Rhoten, Michael Ryks, W. Scott Harmsen, Michael Camilleri

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Aprepitant, an NK1 receptor antagonist, is approved for the treatment of chemotherapy-induced or postoperative emesis by blocking NK1 receptors in the brain stem vomiting center. The effects of NK1 receptors on gastric functions and postprandial symptoms in humans are unclear; a single, crossover study did not show a significant effect of aprepitant on gastrointestinal transit. Our aim was to compare, in a randomized, double-blind, placebo-controlled, parallel-group study (12 healthy volunteers per group), the effects of aprepitant vs. placebo on gastric emptying of solids (by scintigraphy) with a 320-kcal meal, gastric volumes (GVs; fasting and accommodation by single photon emission-computed tomography), satiation [maximum tolerated volume (MTV)], and symptoms after a dyspeptogenic meal of Ensure. Aprepitant (125 mg on day 1, followed by 80 mg on days 2-5) or placebo, one tablet daily, was administered for 5 consecutive days. Statistical analysis was by unpaired rank sum test, adjusted for sex difference and body mass index. To assess treatment effects on symptoms, we incorporated MTV in the model. Aprepitant increased fasting, postprandial, and accommodation GV and tended to increase volume to fullness and MTV by ~200 kcal. However, aprepitant increased aggregate symptoms, nausea, and pain scores after ingestion the MTV of Ensure. There was no significant effect of aprepitant on gastric half-emptying time of solids. We conclude that NK1 receptors are involved in the control of GV and in determining postprandial satiation and symptoms. Further studies of the pharmacodynamics and therapeutic role of NK1 receptor antagonists in patients with gastroparesis and dyspepsia are warranted. NEW & NOTEWORTHY Aprepitant increases fasting, postprandial, and accommodation gastric volumes. Aprepitant increases volume to fullness and maximum tolerated volume during a nutrient drink test. NK1 receptors are involved in the control of gastric volume and in determining postprandial satiation and symptoms.

Original languageEnglish (US)
Pages (from-to)G505-G510
JournalAmerican Journal of Physiology - Gastrointestinal and Liver Physiology
Volume313
Issue number5
DOIs
StatePublished - Nov 2 2017

Fingerprint

aprepitant
Satiation
Stomach
Fasting
Gastric Emptying
Placebos
Meals
Gastrointestinal Transit
Gastroparesis
Postoperative Nausea and Vomiting
Dyspepsia
Nonparametric Statistics
Single-Photon Emission-Computed Tomography

Keywords

  • Gastric motor functions
  • NK1 receptor antagonist
  • Satiation

ASJC Scopus subject areas

  • Physiology
  • Hepatology
  • Gastroenterology
  • Physiology (medical)

Cite this

Effects of nk1 receptors on gastric motor functions and satiation in healthy humans : Results from a controlled trial with the nk1 antagonist aprepitant. / Jacob, Deepti; Busciglio, Irene; Burton, Duane; Halawi, Houssam; Oduyebo, Ibironke; Rhoten, Deborah; Ryks, Michael; Scott Harmsen, W.; Camilleri, Michael.

In: American Journal of Physiology - Gastrointestinal and Liver Physiology, Vol. 313, No. 5, 02.11.2017, p. G505-G510.

Research output: Contribution to journalArticle

Jacob, Deepti ; Busciglio, Irene ; Burton, Duane ; Halawi, Houssam ; Oduyebo, Ibironke ; Rhoten, Deborah ; Ryks, Michael ; Scott Harmsen, W. ; Camilleri, Michael. / Effects of nk1 receptors on gastric motor functions and satiation in healthy humans : Results from a controlled trial with the nk1 antagonist aprepitant. In: American Journal of Physiology - Gastrointestinal and Liver Physiology. 2017 ; Vol. 313, No. 5. pp. G505-G510.
@article{d7bfdad214bd4df6bea6d28dbbeeb03c,
title = "Effects of nk1 receptors on gastric motor functions and satiation in healthy humans: Results from a controlled trial with the nk1 antagonist aprepitant",
abstract = "Aprepitant, an NK1 receptor antagonist, is approved for the treatment of chemotherapy-induced or postoperative emesis by blocking NK1 receptors in the brain stem vomiting center. The effects of NK1 receptors on gastric functions and postprandial symptoms in humans are unclear; a single, crossover study did not show a significant effect of aprepitant on gastrointestinal transit. Our aim was to compare, in a randomized, double-blind, placebo-controlled, parallel-group study (12 healthy volunteers per group), the effects of aprepitant vs. placebo on gastric emptying of solids (by scintigraphy) with a 320-kcal meal, gastric volumes (GVs; fasting and accommodation by single photon emission-computed tomography), satiation [maximum tolerated volume (MTV)], and symptoms after a dyspeptogenic meal of Ensure. Aprepitant (125 mg on day 1, followed by 80 mg on days 2-5) or placebo, one tablet daily, was administered for 5 consecutive days. Statistical analysis was by unpaired rank sum test, adjusted for sex difference and body mass index. To assess treatment effects on symptoms, we incorporated MTV in the model. Aprepitant increased fasting, postprandial, and accommodation GV and tended to increase volume to fullness and MTV by ~200 kcal. However, aprepitant increased aggregate symptoms, nausea, and pain scores after ingestion the MTV of Ensure. There was no significant effect of aprepitant on gastric half-emptying time of solids. We conclude that NK1 receptors are involved in the control of GV and in determining postprandial satiation and symptoms. Further studies of the pharmacodynamics and therapeutic role of NK1 receptor antagonists in patients with gastroparesis and dyspepsia are warranted. NEW & NOTEWORTHY Aprepitant increases fasting, postprandial, and accommodation gastric volumes. Aprepitant increases volume to fullness and maximum tolerated volume during a nutrient drink test. NK1 receptors are involved in the control of gastric volume and in determining postprandial satiation and symptoms.",
keywords = "Gastric motor functions, NK1 receptor antagonist, Satiation",
author = "Deepti Jacob and Irene Busciglio and Duane Burton and Houssam Halawi and Ibironke Oduyebo and Deborah Rhoten and Michael Ryks and {Scott Harmsen}, W. and Michael Camilleri",
year = "2017",
month = "11",
day = "2",
doi = "10.1152/ajpgi.00197.2017",
language = "English (US)",
volume = "313",
pages = "G505--G510",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "5",

}

TY - JOUR

T1 - Effects of nk1 receptors on gastric motor functions and satiation in healthy humans

T2 - Results from a controlled trial with the nk1 antagonist aprepitant

AU - Jacob, Deepti

AU - Busciglio, Irene

AU - Burton, Duane

AU - Halawi, Houssam

AU - Oduyebo, Ibironke

AU - Rhoten, Deborah

AU - Ryks, Michael

AU - Scott Harmsen, W.

AU - Camilleri, Michael

PY - 2017/11/2

Y1 - 2017/11/2

N2 - Aprepitant, an NK1 receptor antagonist, is approved for the treatment of chemotherapy-induced or postoperative emesis by blocking NK1 receptors in the brain stem vomiting center. The effects of NK1 receptors on gastric functions and postprandial symptoms in humans are unclear; a single, crossover study did not show a significant effect of aprepitant on gastrointestinal transit. Our aim was to compare, in a randomized, double-blind, placebo-controlled, parallel-group study (12 healthy volunteers per group), the effects of aprepitant vs. placebo on gastric emptying of solids (by scintigraphy) with a 320-kcal meal, gastric volumes (GVs; fasting and accommodation by single photon emission-computed tomography), satiation [maximum tolerated volume (MTV)], and symptoms after a dyspeptogenic meal of Ensure. Aprepitant (125 mg on day 1, followed by 80 mg on days 2-5) or placebo, one tablet daily, was administered for 5 consecutive days. Statistical analysis was by unpaired rank sum test, adjusted for sex difference and body mass index. To assess treatment effects on symptoms, we incorporated MTV in the model. Aprepitant increased fasting, postprandial, and accommodation GV and tended to increase volume to fullness and MTV by ~200 kcal. However, aprepitant increased aggregate symptoms, nausea, and pain scores after ingestion the MTV of Ensure. There was no significant effect of aprepitant on gastric half-emptying time of solids. We conclude that NK1 receptors are involved in the control of GV and in determining postprandial satiation and symptoms. Further studies of the pharmacodynamics and therapeutic role of NK1 receptor antagonists in patients with gastroparesis and dyspepsia are warranted. NEW & NOTEWORTHY Aprepitant increases fasting, postprandial, and accommodation gastric volumes. Aprepitant increases volume to fullness and maximum tolerated volume during a nutrient drink test. NK1 receptors are involved in the control of gastric volume and in determining postprandial satiation and symptoms.

AB - Aprepitant, an NK1 receptor antagonist, is approved for the treatment of chemotherapy-induced or postoperative emesis by blocking NK1 receptors in the brain stem vomiting center. The effects of NK1 receptors on gastric functions and postprandial symptoms in humans are unclear; a single, crossover study did not show a significant effect of aprepitant on gastrointestinal transit. Our aim was to compare, in a randomized, double-blind, placebo-controlled, parallel-group study (12 healthy volunteers per group), the effects of aprepitant vs. placebo on gastric emptying of solids (by scintigraphy) with a 320-kcal meal, gastric volumes (GVs; fasting and accommodation by single photon emission-computed tomography), satiation [maximum tolerated volume (MTV)], and symptoms after a dyspeptogenic meal of Ensure. Aprepitant (125 mg on day 1, followed by 80 mg on days 2-5) or placebo, one tablet daily, was administered for 5 consecutive days. Statistical analysis was by unpaired rank sum test, adjusted for sex difference and body mass index. To assess treatment effects on symptoms, we incorporated MTV in the model. Aprepitant increased fasting, postprandial, and accommodation GV and tended to increase volume to fullness and MTV by ~200 kcal. However, aprepitant increased aggregate symptoms, nausea, and pain scores after ingestion the MTV of Ensure. There was no significant effect of aprepitant on gastric half-emptying time of solids. We conclude that NK1 receptors are involved in the control of GV and in determining postprandial satiation and symptoms. Further studies of the pharmacodynamics and therapeutic role of NK1 receptor antagonists in patients with gastroparesis and dyspepsia are warranted. NEW & NOTEWORTHY Aprepitant increases fasting, postprandial, and accommodation gastric volumes. Aprepitant increases volume to fullness and maximum tolerated volume during a nutrient drink test. NK1 receptors are involved in the control of gastric volume and in determining postprandial satiation and symptoms.

KW - Gastric motor functions

KW - NK1 receptor antagonist

KW - Satiation

UR - http://www.scopus.com/inward/record.url?scp=85032880680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032880680&partnerID=8YFLogxK

U2 - 10.1152/ajpgi.00197.2017

DO - 10.1152/ajpgi.00197.2017

M3 - Article

C2 - 28814387

AN - SCOPUS:85032880680

VL - 313

SP - G505-G510

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 5

ER -